RALEIGH, N.C. , March 27, 2018 -- Syneos Health™ (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that the company is a founding member of Align Clinical CRO. This new industry technology standards group is dedicated to making it easier for the life sciences industry to run clinical trials with CROs to bring products to market faster and more efficiently.
“Smart collaboration – identifying better and faster methods to deliver medicines to patients – is at the heart of everything we do at Syneos Health,” says Rachel Stahler, Chief Information Officer. “Within our organization, we’ve purposefully removed the silos between the clinical and commercial disciplines to provide solutions that improve operational delivery and enable our customers to speed therapies to patients. We’re thrilled to bring this spirit of collaboration to Align Clinical CRO, where we’ll work in partnership with our industry peers to transform clinical trial execution.”
Align Clinical CRO represents a first-ever global effort where CROs are joining forces to develop open technology standards to transform clinical trial operations. The organization, which launched today, brings together six leading CROs planning to help create open technology standards intended to simplify trial execution and improve the productivity and efficiency of clinical trials for sponsors.
Syneos Health brings deep industry knowledge to Align Clinical CRO, including in-depth clinical and commercial expertise and integrated, multi-disciplinary perspectives. This knowledge transfer also includes technology competencies such as clinical data systems, as well as commercial insights that can inform accelerated trial design and execution.
“There’s tremendous potential to enhance clinical trial execution through common technology standards that will benefit the entire industry,” said Henry Levy, President of Align Clinical CRO. “Align Clinical CRO represents an important industry collaboration to improve the trial processes and how the industry works together to accelerate drug development.”
For more information on Align Clinical CRO, visit www.alignclinicalcro.org to learn about its mission and stay up-to-date on the standards in development.
About Syneos Health
Syneos Health (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Created through the merger of two industry leading companies – INC Research and inVentiv Health – we bring together more than 21,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to life™ visit syneoshealth.com.
About Align Clinical CRO
Align Clinical CRO is an industry standards group founded by Veeva Systems and the world’s largest CROs, including ICON plc, Medpace, Pharmaceutical Product Development LLC (PPD), PRA Health Sciences, Syneos Health, and UBC. The group is dedicated to creating open technology standards that improve trial execution and collaboration with life sciences companies, making it easier for sponsors and CROs to work together during clinical trials. For more information, visit www.alignclinicalcro.org.
| Contact: | |
| Investor Relations Contact: | Press/Media Contact: |
| Ronnie Speight | Danielle DeForge |
| Vice President, Investor Relations | Senior Director, External Communications |
| +1 919 745 2745 | +1 202 210 5992 |
| [email protected] | [email protected] |


Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation
DHL Q2 Profit Jumps 24% as Express Business Drives Growth
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 



